Mobile

Phase III randomized, placebo controlled study of sorafenib in repeated cycles of 21 days in combination with paclitaxel/carboplatin chemotherapy in subjects with unresectable stage III or stage IV me...

Mise à jour : Il y a 4 ans
Référence : EUCTR2005-000941-12

Phase III randomized, placebo controlled study of sorafenib in repeated cycles of 21 days in combination with paclitaxel/carboplatin chemotherapy in subjects with unresectable stage III or stage IV melanoma

Femme et Homme

  • | Pays :
    • -
  • | Organes :
    • -
  • | Spécialités :
    • -

Extrait

To evaluate progression free survival (PFS) between subjects treated with sorafenib versus placebo in combination with paclitaxel and carboplatin.

Critère d'inclusion

  • unresectable, advanced Stage III or Stage IV melanoma

Liens